According to the results obtained from the analysis of the THP-1 supernatants and from the “in-gel” zymography of a pool of sera from patients with breast cancer, we can hypothesize that, as suggested by other authors, the antioxidant compounds used in this study can inhibit MMPs through different mechanisms, involving the inhibition of both MMP activity and expression, with the latter occurring through the downregulation of different signaling pathways involved in MMP-2 and MMP-9 gene transcription (Figure 7). The gene discussed is MMP9; the disease is breast carcinoma.